Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282826 | PMC |
| http://dx.doi.org/10.1186/s13048-024-01481-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Author Correction: Novel mechanism whereby metformin improves glucose homeostasis: TXNIP-GLUT1 axis modulation enhances intestinal glucotonic effects.
Exp Mol Med
September 2025
Endocrinology, Institute of Endocrine Research, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Therapeutic potential of the novel anthraquinone compound ESE in T2DM mice by inhibiting of TLR4/MyD88/NF-κB pathway.
Int Immunopharmacol
August 2025
Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy. Harbin Medical University, Harbin 150081, China; Chinese Medicine Guangdong Laboratory, Guangdong, Hengqin, Chin
Background And Objective: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and pancreatic β-cell dysfunction. Although current medications such as metformin can effectively control blood glucose levels, their ability to improve β-cell function and suppress chronic inflammation remains limited. Emodin, a natural compound with anti-inflammatory, antioxidant, and insulin-sensitizing properties, has shown therapeutic promise; however, its clinical application is constrained by poor water solubility and low bioavailability.
View Article and Find Full Text PDFCorrection: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial.
Front Oncol
August 2025
Medical Oncology, Healthcare Global, Bangalore, India.
[This corrects the article DOI: 10.3389/fonc.2025.
View Article and Find Full Text PDFCombined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
Diabetes Obes Metab
August 2025
Kallyope, Inc., New York, New York, USA.
Aims: K-757 and K-833 are novel full agonists of GPR40 and GPR119, respectively, which are nutrient receptors co-expressed on both pancreatic beta cells and gut enteroendocrine cells that signal through complementary mechanisms. We sought to assess the effects on glucose control and body weight following co-administration of K-757 and K-833.
Materials And Methods: We conducted two randomized, double-blind, placebo-controlled Phase 1 studies in overweight-obese subjects with T2DM maintained on metformin to characterize the effects on secretion of gut incretin and appetite-regulating hormones, glucose control and body weight following combined therapy with K-757 and K-833.